インテグラーゼ阻害剤の世界市場レポート 2025年

インテグラーゼ阻害剤市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は6.7%で、61億米ドルに成長します。今後は、HIV感染者の増加、HIV治療オプションに対する意識の高まり、予防療法の拡大、長時間作用型注射剤の台頭、保険・償還の適用範囲の拡大などが予測期間の成長を牽引するとみられます。この期間に予想される主な動向には、長時間作用型注射剤の採用、デジタルおよび遠隔医療サービスの統合、個別化されたHIV治療アプローチ、技術の発展、小児用製剤の開発などがあります

HIV 感染率の増加により、インテグラーゼ阻害剤市場の成長が促進されると予想されます。HIVは、ヒト免疫不全ウイルスによって引き起こされる長期のウイルス感染症であり、CD4+T細胞を標的とし破壊することによって免疫系を損ない、それによって他の病気に対する脆弱性を高めます。HIV感染者の増加は、質の高いヘルスケアへのアクセスが不十分であることが主な原因であり、特に十分なサービスを受けていない人々における予防、診断、治療の取り組みが制限されています。インテグラーゼ阻害剤は、HIV治療において、ウイルスがその遺伝物質をヒトのDNAに組み込むのを阻止することにより、ウイルスの複製を抑制し、感染制御を助けるという重要な役割を果たします。例えば、2024年10月、gov.ukによると、イングランドでは2023年に6,008件の新規HIV診断が記録され、2022年の3,975件から51％増加しました。

インテグラーゼ阻害剤市場の主要企業は、患者の服薬アドヒアランスを促進し、使いやすさを向上させ、抗レトロウイルス薬の安全かつ効率的な投与を保証するため、特に長期的なHIV治療を受けている患者を対象に、単位用量包装などの革新的な包装ソリューションに注力しています。単位用量包装は、用量が個別に密封されており、正確な投与、取り扱いの容易さ、薬剤の安全性の向上をサポートします。例えば、2024年2月、HIV治療を専門とする英国の製薬会社であるヴィーブヘルスケアは、ブリスターパック形態のドバト（ドルテグラビル／ラミブジン）を米国で発売しました。この製品は、抗レトロウイルス療法を初めて受けるか、ウイルス学的に抑制されている（HIV-1 RNA<50コピー/mL）成人HIV-1患者であって、過去に治療失敗がなく、ドバトの成分に対する耐性が知られていない患者に対する完全レジメンとして承認されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界インテグラーゼ阻害剤PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のインテグラーゼ阻害剤市場：成長率分析
• 世界のインテグラーゼ阻害剤市場の実績：規模と成長、2019～2024年
• 世界のインテグラーゼ阻害剤市場の予測：規模と成長、2024～2029年、2034年
• 世界インテグラーゼ阻害剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のインテグラーゼ阻害剤市場：薬剤別、実績と予測、2019～2024年、2024～2029年、2034年
• ラルテグラビル
• ドルタグラビル
• エルビテグラビル
• ビクテグラビル
• 世界のインテグラーゼ阻害剤市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• オーラル
• 静脈内
• 皮下
• 世界のインテグラーゼ阻害剤市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のインテグラーゼ阻害剤市場：治癒領域別、実績と予測、2019～2024年、2024～2029年、2034年
• HIV感染
• HCV感染
• その他のウイルス感染症
• 世界のインテグラーゼ阻害剤市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• クリニック
• 調査機関
• 世界のインテグラーゼ阻害剤市場：ラルテグラビルの種類別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口錠
• 経口懸濁液
• 静脈内（IV）注射
• 世界のインテグラーゼ阻害剤市場：ドルテグラビルの種類別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口錠
• 経口懸濁液
• 世界のインテグラーゼ阻害剤市場：エルビテグラビルの種類別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口錠
• 経口懸濁液
• 世界のインテグラーゼ阻害剤市場：ビクテグラビルの種類別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口錠

第7章 地域別・国別分析

• 世界のインテグラーゼ阻害剤市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のインテグラーゼ阻害剤市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• インテグラーゼ阻害剤市場：競合情勢
• インテグラーゼ阻害剤市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline PLC Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Gilead Sciences
• Boehringer Ingelheim
• Viatris Inc.
• Hetero Pharmaceuticals
• ViiV Healthcare
• Apotex
• Shionogi Co. ltd.
• Aurobindo Pharma
• Dr. Reddy's Laboratories
• Cipla Limited
• Lupin Limited
• Torii Pharmaceutical Co. Ltd
• Theratechnologies Inc.
• Adooq Bioscience
• Aetos Pharma

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• インテグラーゼ阻害剤市場、2029年：新たな機会を提供する国
• インテグラーゼ阻害剤市場、2029年：新たな機会を提供するセグメント
• インテグラーゼ阻害剤市場、2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Integrase inhibitors are a class of antiretroviral drugs that block the action of the HIV enzyme integrase, preventing the integration of viral DNA into the host cell's genome. This inhibition stops the replication of the virus and slows the progression of HIV infection. These inhibitors are primarily used in the treatment of HIV, typically as part of combination therapy to lower viral load and enhance immune function.

The main drug types within integrase inhibitors include raltegravir, dolutegravir, elvitegravir, and bictegravir. Raltegravir is an antiretroviral medication that treats HIV-1 infection by inhibiting the integrase enzyme, thereby preventing the virus from integrating its genetic material into the host's DNA. These drugs are administered through various routes, including oral, intravenous, and subcutaneous, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. Their therapeutic indications include HIV infection, HCV infection, and other viral infections. The key end users of these drugs are hospitals, clinics, and research institutions.

The integrase inhibitors market research report is one of a series of new reports from The Business Research Company that provides integrase inhibitors market statistics, including the integrase inhibitors industry global market size, regional shares, competitors with the integrase inhibitors market share, detailed integrase inhibitors market segments, market trends, and opportunities, and any further data you may need to thrive in the integrase inhibitors industry. This integrase inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The integrase inhibitors market size has grown strongly in recent years. It will grow from $4.40 billion in 2024 to $4.71 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth during the historic period can be attributed to the rising prevalence of HIV, increased global awareness and improvements in treatment, government initiatives and funding, a rise in HIV diagnoses and testing, and the aging HIV population.

The integrase inhibitors market size is expected to see strong growth in the next few years. It will grow to $6.10 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. Looking ahead, growth in the forecast period is expected to be driven by an increase in HIV infections, greater awareness about HIV treatment options, the expansion of preventive therapies, the rise of long-acting injectable treatments, and the expansion of insurance and reimbursement coverage. Key trends expected during this period include the adoption of long-acting injectables, integration of digital and telehealth services, personalized HIV treatment approaches, technological advancements, and the development of pediatric formulations.

The increasing prevalence of HIV infections is anticipated to drive the growth of the integrase inhibitors market. HIV is a long-term viral infection caused by the human immunodeficiency virus, which compromises the immune system by targeting and destroying CD4+ T cells, thereby heightening vulnerability to other illnesses. The rise in HIV cases is largely attributed to inadequate access to quality healthcare, which limits prevention, diagnostic, and treatment efforts, particularly in underserved populations. Integrase inhibitors play a key role in HIV therapy by preventing the virus from integrating its genetic material into human DNA, thereby suppressing viral replication and aiding in infection control, which may contribute to reducing HIV prevalence. For example, in October 2024, gov.uk reported that England recorded 6,008 new HIV diagnoses in 2023, a 51% increase from 3,975 cases in 2022. Thus, the growing number of HIV infections is expected to support the expansion of the integrase inhibitors market.

Leading companies in the integrase inhibitors market are concentrating on innovative packaging solutions, such as unit dose packaging, to promote patient adherence, enhance ease of use, and ensure the secure and efficient administration of antiretroviral drugs, particularly for individuals undergoing long-term HIV treatment. Unit dose packaging involves individually sealed doses, which support accurate dosing, ease of handling, and improved medication safety. For instance, in February 2024, ViiV Healthcare, a UK-based pharmaceutical company dedicated to HIV treatments, introduced Dovato (dolutegravir/lamivudine) in blister pack form in the United States. This product is approved as a complete regimen for adults with HIV-1 who are either new to antiretroviral therapy or virologically suppressed (HIV-1 RNA <50 copies/mL) with no prior treatment failures or known resistance to Dovato's components.

In April 2024, ViiV Healthcare collaborated with the Medicines Patent Pool (MPP) to broaden access to dolutegravir (DTG)-based HIV medications. This partnership has facilitated the distribution of over one billion packs of generic DTG treatments to 24 million individuals living with HIV across 128 low- and middle-income countries, significantly enhancing accessibility and treatment outcomes. The Medicines Patent Pool, based in Switzerland, is a non-profit organization that negotiates patent licenses to improve access to essential medicines.

Major players in the integrase inhibitors market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bristol-Myers squibb Company, GlaxoSmithKline PLC, Gilead Sciences, Boehringer Ingelheim, Viatris Inc., Hetero Pharmaceuticals, ViiV Healthcare, Apotex, Shionogi Co. ltd., Aurobindo Pharma, Dr. Reddy's Laboratories, Cipla Limited, Lupin Limited, Torii Pharmaceutical Co. Ltd, Theratechnologies Inc., Adooq Bioscience, and Aetos Pharma.

North America was the largest region in the integrase inhibitors market in 2024. The regions covered in integrase inhibitors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the integrase inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The integrase inhibitors market consists of sales of tablets, capsules, fixed-dose combination drugs, and injectable formulations. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Integrase Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on integrase inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for integrase inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The integrase inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drugs: Raltegravir; Dolutagravir; Elvitegravir; Bictegravir
• 2) By Route of Administration: Oral; Intravenous; Subcutaneous
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 4) By Therapeutic Area: HIV Infection; HCV Infection; Other Viral Infections
• 5) By End User: Hospitals; Clinics; Research Institutes
• Subsegments:
• 1) By Raltegravir: Oral Tablet; Oral Suspension; Intravenous (IV) Injection
• 2) By Dolutegravir: Oral Tablet; Oral Suspension
• 3) By Elvitegravir: Oral Tablet; Oral Suspension
• 4) By Bictegravir: Oral Tablet
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; Bristol-Myers squibb Company; GlaxoSmithKline PLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Integrase Inhibitors Market Characteristics

3. Integrase Inhibitors Market Trends And Strategies

4. Integrase Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Integrase Inhibitors Growth Analysis And Strategic Analysis Framework

• 5.1. Global Integrase Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Integrase Inhibitors Market Growth Rate Analysis
• 5.4. Global Integrase Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Integrase Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Integrase Inhibitors Total Addressable Market (TAM)

6. Integrase Inhibitors Market Segmentation

• 6.1. Global Integrase Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Raltegravir
• Dolutagravir
• Elvitegravir
• Bictegravir
• 6.2. Global Integrase Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• Subcutaneous
• 6.3. Global Integrase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Integrase Inhibitors Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• HIV Infection
• HCV Infection
• Other Viral Infections
• 6.5. Global Integrase Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Research Institutes
• 6.6. Global Integrase Inhibitors Market, Sub-Segmentation Of Raltegravir, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Tablet
• Oral Suspension
• Intravenous (IV) Injection
• 6.7. Global Integrase Inhibitors Market, Sub-Segmentation Of Dolutegravir, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Tablet
• Oral Suspension
• 6.8. Global Integrase Inhibitors Market, Sub-Segmentation Of Elvitegravir, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Tablet
• Oral Suspension
• 6.9. Global Integrase Inhibitors Market, Sub-Segmentation Of Bictegravir, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Tablet

7. Integrase Inhibitors Market Regional And Country Analysis

• 7.1. Global Integrase Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Integrase Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Integrase Inhibitors Market

• 8.1. Asia-Pacific Integrase Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Integrase Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Integrase Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Integrase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Integrase Inhibitors Market

• 9.1. China Integrase Inhibitors Market Overview
• 9.2. China Integrase Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Integrase Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Integrase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Integrase Inhibitors Market

• 10.1. India Integrase Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Integrase Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Integrase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Integrase Inhibitors Market

• 11.1. Japan Integrase Inhibitors Market Overview
• 11.2. Japan Integrase Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Integrase Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Integrase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Integrase Inhibitors Market

• 12.1. Australia Integrase Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Integrase Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Integrase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Integrase Inhibitors Market

• 13.1. Indonesia Integrase Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Integrase Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Integrase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Integrase Inhibitors Market

• 14.1. South Korea Integrase Inhibitors Market Overview
• 14.2. South Korea Integrase Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Integrase Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Integrase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Integrase Inhibitors Market

• 15.1. Western Europe Integrase Inhibitors Market Overview
• 15.2. Western Europe Integrase Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Integrase Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Integrase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Integrase Inhibitors Market

• 16.1. UK Integrase Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Integrase Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Integrase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Integrase Inhibitors Market

• 17.1. Germany Integrase Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Integrase Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Integrase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Integrase Inhibitors Market

• 18.1. France Integrase Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Integrase Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Integrase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Integrase Inhibitors Market

• 19.1. Italy Integrase Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Integrase Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Integrase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Integrase Inhibitors Market

• 20.1. Spain Integrase Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Integrase Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Integrase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Integrase Inhibitors Market

• 21.1. Eastern Europe Integrase Inhibitors Market Overview
• 21.2. Eastern Europe Integrase Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Integrase Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Integrase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Integrase Inhibitors Market

• 22.1. Russia Integrase Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Integrase Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Integrase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Integrase Inhibitors Market

• 23.1. North America Integrase Inhibitors Market Overview
• 23.2. North America Integrase Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Integrase Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Integrase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Integrase Inhibitors Market

• 24.1. USA Integrase Inhibitors Market Overview
• 24.2. USA Integrase Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Integrase Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Integrase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Integrase Inhibitors Market

• 25.1. Canada Integrase Inhibitors Market Overview
• 25.2. Canada Integrase Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Integrase Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Integrase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Integrase Inhibitors Market

• 26.1. South America Integrase Inhibitors Market Overview
• 26.2. South America Integrase Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Integrase Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Integrase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Integrase Inhibitors Market

• 27.1. Brazil Integrase Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Integrase Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Integrase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Integrase Inhibitors Market

• 28.1. Middle East Integrase Inhibitors Market Overview
• 28.2. Middle East Integrase Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Integrase Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Integrase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Integrase Inhibitors Market

• 29.1. Africa Integrase Inhibitors Market Overview
• 29.2. Africa Integrase Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Integrase Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Integrase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Integrase Inhibitors Market Competitive Landscape And Company Profiles

• 30.1. Integrase Inhibitors Market Competitive Landscape
• 30.2. Integrase Inhibitors Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol-Myers squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline PLC Overview, Products and Services, Strategy and Financial Analysis

31. Integrase Inhibitors Market Other Major And Innovative Companies

• 31.1. Gilead Sciences
• 31.2. Boehringer Ingelheim
• 31.3. Viatris Inc.
• 31.4. Hetero Pharmaceuticals
• 31.5. ViiV Healthcare
• 31.6. Apotex
• 31.7. Shionogi Co. ltd.
• 31.8. Aurobindo Pharma
• 31.9. Dr. Reddy's Laboratories
• 31.10. Cipla Limited
• 31.11. Lupin Limited
• 31.12. Torii Pharmaceutical Co. Ltd
• 31.13. Theratechnologies Inc.
• 31.14. Adooq Bioscience
• 31.15. Aetos Pharma

32. Global Integrase Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Integrase Inhibitors Market

34. Recent Developments In The Integrase Inhibitors Market

35. Integrase Inhibitors Market High Potential Countries, Segments and Strategies

• 35.1 Integrase Inhibitors Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Integrase Inhibitors Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Integrase Inhibitors Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer